MELBOURNE, Australia--(BUSINESS WIRE)--
Propanc
Biopharma, Inc. (OTCQB: PPCB) ("Propanc"), a clinical stage
biopharmaceutical company focused on development of new and proprietary
treatments for cancer patients suffering from solid tumors such as
pancreatic, ovarian and colorectal cancers, today announced that Propanc
has selected LaVoieHealthScience (“LHS”) as its communications agency of
record. LHS is an integrated investor and public relations agency
focused on advancing health and science innovations. Propanc is
partnering with LHS to develop corporate awareness of Propanc as a
health science innovator as it transitions its lead technology into
human clinical trials.

Propanc is developing new cancer treatments targeting high-risk
patients, particularly cancer survivors, who need a follow-up,
non-toxic, long-term therapy designed to prevent cancer from returning
and spreading. Its lead product, PRP, is an enhanced proenzyme
formulation designed to enhance the anti-cancer effects of multiple
enzymes acting synergistically. The company’s initial target patient
populations include pancreatic, ovarian and colorectal cancers.
Propanc’s treatment for pancreatic cancer received Orphan Drug
Designation by the U.S. Food and Drug Administration in 2017. For more
information on PRP’s Mechanism of Action, view this video at: http://www.propanc.com/news-media/video

“As we move closer to the clinical trials stage, it’s critically
important to build the right reputation amongst key stakeholders. LHS,
with its proven track record in providing integrated communications to
global health science innovators, will be a great long-term partner as
we continue to drive PRP forward with our drug discovery efforts,” said
James Nathanielsz, CEO and Executive Chairman of Propanc. “LHS stood out
with its deep understanding of our value proposition across targeted
channels and audiences, its team of high-touch senior communicators, and
proprietary approach to creating targeted messaging mapped to
stakeholders as the underpinning of a strategic communications program.
We are looking forward to a long and productive relationship.”

Donna L. LaVoie, President & CEO of LHS commented, “We are delighted to
be working with the Propanc Biopharma team to bring attention to their
pioneering work targeting cancer stem cells. We look forward to
supporting Propanc Biopharma as it brings novel therapies into the
clinical trials stage to provide new hope for patients suffering from
metastatic cancer.”

About Propanc Biopharma, Inc.:

Propanc Biopharma, Inc. (the "Company") is a biopharmaceutical company
developing new cancer treatments initially for patients suffering from
pancreatic, ovarian and colorectal cancers. The Company has developed a
formulation of anti-cancer compounds, which exert a number of effects
designed to control or prevent tumors from recurring and spreading
throughout the body by targeting and eradicating cancer stem cells. The
Company's products involve or employ pancreatic proenzymes, which are
inactive precursors of enzymes. In the near term, the Company intends to
target patients with limited remaining therapeutic options for the
treatment of solid tumors. In the future, the Company intends to develop
its lead product candidate, PRP, to treat early stage cancer and
pre-cancerous diseases, and as a preventative measure for patients at
risk of developing cancer based on genetic screening.

PRP is a solution for intravenous administration of a combination of two
pancreatic proenzymes trypsinogen and chymotrypsinogen. Progressing
towards a first-in-human study, PRP seeks to prevent recurrence and
metastasis from solid tumors by targeting and eradicating cancer stem
cells. Eighty percent of cancers are solid tumors and metastasis is the
main cause of patient death from cancer. According to the World Health
Organization, 8.2 million people died from cancer in 2012. A report by
IMS Health states innovative therapies are driving the global oncology
market to meet demand, which is expected to reach $150 billion by 2020.
The Company's initial target patient populations are pancreatic, ovarian
and colorectal cancers, representing an estimated combined market
segment of $14 billion in 2020, according to GBI Research.

All statements other than statements of historical facts contained in
this press release are "forward-looking statements," which may often,
but not always, be identified by the use of such words as "may,"
"might," "will," "will likely result," "would," "should," "estimate,"
"plan," "project," "forecast," "intend," "expect," "anticipate,"
"believe," "seek," "continue," "target" or the negative of such terms or
other similar expressions. These statements involve known and unknown
risks, uncertainties and other factors, which may cause actual results,
performance or achievements to differ materially from those expressed or
implied by such statements. These factors include uncertainties as to
the Company's ability to continue as a going concern absent new debt or
equity financings; the Company's current reliance on substantial debt
financing that it is unable to repay in cash; the Company's ability to
successfully remediate material weaknesses in its internal controls; the
Company's ability to reach research and development milestones as
planned and within proposed budgets; the Company's ability to control
costs; the Company's ability to obtain adequate new financing on
reasonable terms; the Company's ability to successfully develop PRP, its
lead product candidate; the Company's ability to obtain and maintain
patent protection; the Company's ability to recruit employees and
directors with accounting and finance expertise; the Company's
dependence on third parties for services; the Company dependence on key
executives; the impact of government regulations, including FDA
regulations; the impact of any future litigation; the availability of
capital; changes in economic conditions, competition; and other risks,
including, but not limited to, those described in the Company's
Registration Statement on Form S-1, filed with the U.S. Securities and
Exchange Commission (the "SEC") on October 17, 2018, and in the
Company's other filings and submissions with the SEC. These
forward-looking statements speak only as of the date hereof and the
Company disclaims any obligations to update these statements except as
may be required by law.